Senhwa Biosciences, Inc. (TPEX:6492)
Taiwan · Delayed Price · Currency is TWD 41.25
-0.25 (-0.60%)
At close: Dec 4, 2025
Senhwa Biosciences Revenue
Senhwa Biosciences had revenue of 330.00K TWD in the quarter ending September 30, 2025, with 32.00% growth. This brings the company's revenue in the last twelve months to 1.08M, up 8.00% year-over-year. In the year 2024, Senhwa Biosciences had annual revenue of 1.00M.
Revenue (ttm)
1.08M
Revenue Growth
+8.00%
P/S Ratio
3,336.20
Revenue / Employee
n/a
Employees
n/a
Market Cap
3.60B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.00M | - | - |
| Dec 31, 2023 | 1.00M | - | - |
| Dec 31, 2022 | 1.00M | 450.00K | 81.82% |
| Dec 31, 2021 | 550.00K | -67.00K | -10.86% |
| Dec 31, 2020 | 617.00K | 317.00K | 105.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bora Pharmaceuticals Co., LTD. | 21.10B |
| Lotus Pharmaceutical | 18.66B |
| PharmaEssentia | 13.82B |
| Pegavision | 6.90B |
| Center Laboratories | 1.57B |
| EirGenix | 936.18M |
| Oneness Biotech | 117.33M |
| Polaris Group | 70.83M |
Senhwa Biosciences News
- 3 months ago - Basal Cell Neoplasms Clinical Trial Pipeline Accelerates as 22+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Benzinga